ClinicalTrials.gg
CompletedNCT03963167Updated Feb 20, 2026

Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)

An observational study in COPD, sponsored by Chiesi Italia. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Chiesi Italia (part of Chiesi Farmaceutici S.p.A.) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
661
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. — 5 open to participants now, 5 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Chiesi Farmaceutici S.p.A..

Started
2019
with 3 others
Observational
9 of 68
5 open now
Registered
46th of 68
by date

Among the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., this one is one of 4 that started in 2019, is one of 9 observational ones, and was the 46th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

5 of the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

The mean objectives are to evaluate the impact of BDP/FF/G fixed combination on health-status and adherence

03

Conditions studied

  • COPD

Keywords

  • COPD
  • Adherence
  • HRQoL determinants
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

COPD patients with symptoms and history of exacerbations despite of maintenance therapy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written to participate in the study;
  2. Adult patients of either sex aged ≥ 40 years;
  3. Patients with diagnosis of moderate to very severe according to Gold Initiative for Chronic Obstructive Lung Disease (GOLD) updated 2019 (GOLD Stage 2-4);
  4. COPD assessment test (CAT) score ≥ 10 at initiation of BDP/FF/G fixed combination;
  5. History of >1 moderate or severe COPD exacerbation during the previous year.
  6. Patients in treatment with BDP/FF/G as per local clinical practice and according to Trimbow® Summary of Product Characteristics (SmPC).

Exclusion criteria

Exclusion Criteria:

  1. According on Investigator's judgement, patients unable to comply with the requirements of the study (e.g. inability to attend all the planned study visits according to the time limits included) or patients with poorly controlled concomitant severe diseases or conditions that could interfere with the study participation;
  2. Participation in an interventional clinical trial within 30 days prior to enrolment into the present study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
661 participants (actual)
Patient registry
No

Groups and cohorts

  • Patient in treatment with BDP/FF/G fixed combination

    Drug: BDP/FF/G fixed combination

Interventions

  • DrugBDP/FF/G fixed combination

    Fixed combination of Inhaled Corticosteroid (ICS) / Long-acting β2-agonist (LABA) / long-acting muscarinic antagonist (LAMA) that contains Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (G).

    Also known as: Trimbow

06

What researchers measure

Primary outcomes

  1. Change in COPD Assessment Test (CAT) score

    CAT consists of 8 items scored on a scale of 1 to 5, with a total score range of 0-40. A higher score denotes a more severe impact of COPD on the patient's life.

    Time frame: 12 months

Secondary outcomes

  1. Change in COPD Assessment Test (CAT) score

    CAT consists of 8 items scored on a scale of 1 to 5, with a total score range of 0-40. A higher score denotes a more severe impact of COPD on the patient's life.

    Time frame: 6 months

  2. Change in 12-item Test of Adherence to Inhalers (TAI-12) score

    TAI comprises a patient domain (including 10 items) and a healthcare professional domain (including 2 items). Each item ranges from 1 (lowest adherence) to 5 (highest adherence) points. The patient domain score ranges from 10 to 50. Adherence is rated as good (score =50), intermediate (score = 46-49), or poor (score ≤45). The questions for healthcare professionals are scored with 1 or 2 points (poor or good knowledge of the regimen and/or inhalation technique).

    Time frame: 6 and 12 months

  3. Change in COPD and Asthma Sleep Impact Scale (CASIS) score

    It is a self-administered 7-item scale scored on a five-point scale ranging from 0 if the item never applies, to 4 if the item applies very often. A total raw score is produced from the sum of the seven individual scores which is then linearly transformed to a 0-100 total scale score. Higher scores representing greater sleep deterioration in the previous week.

    Time frame: 6 and 12 months

  4. Change in EuroQoL score

    Il consists of 2 pages, a descriptive system and a visual Analogue scale. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each dimension having 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. This decision results in a 1-digit number expressing the level selected for that dimension. The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state.The VAS records the respondent's self-rated health on a 10 cm vertical VAS with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'.

    Time frame: 6 and 12 months

  5. Change of an 8-item questionnaire on satisfaction and usability of the device score from baseline (Visit 1)

    it contains 8 questions, each scored on a 0-5 Likert scale, which range from 0 (fully disagree) to 5 (fully agree), for a total maximum score of 40. Higher scores indicate a higher ease of use and satisfaction with the inhaler

    Time frame: 6 and 12 months

  6. Forced Expiratory Volume in the first second (FEV1, L)

    Time frame: Baseline, 6 and 12 months

  7. Forced Vital Capacity (FVC, L)

    Time frame: Baseline, 6 and 12 months

  8. Mean forced expiratory flow between 25% and 75% of the FVC (FEF25-75)

    Taken from the test with the highest values of FEV1 and FVC

    Time frame: Baseline, 6 and 12 months

  9. Ratio FEV1/FVC

    Derived from these highest values of each parameter

    Time frame: Baseline, 6 and 12 months

  10. Use of rescue medication

    Use of rescue medication

    Time frame: Baseline, 6 and 12 months

  11. Exacerbations

    Moderate to severe exacerbations

    Time frame: Baseline, 6 and 12 months

  12. Adverse events

    Number of adverse events

    Time frame: Baseline, 6 and 12 months

  13. Economic resources consumption

    Number of hospitalizations, ER access, unscheduled visits

    Time frame: Baseline, 6 and 12 months

07

Study locations

1 site
  • Fondazione Policlinico Gemelli
    Rome, Italy
08

References and documents

Publications

  • Richeldi L, Piraino A, Macagno F, Micarelli G, Ingrassia E. The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease (COPD) in an Italian Context of Real Life: The TRITRIAL Study Protocol. Int J Chron Obstruct Pulmon Dis. 2021 Jan 27;16:159-166. doi: 10.2147/COPD.S286559. eCollection 2021. PubMed 33536751 ↗
  • Richeldi L, Schino P, Bargagli E, Ricci A, Rocca A, Marchesani F, Pennisi A, Camiciottoli G, D'Amato M, Macagno F, Scaffidi Argentina U, Ingrassia E, Piraino A. TRITRIAL: The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease in an Italian Context of Real Life. Int J Chron Obstruct Pulmon Dis. 2024 Feb 23;19:475-487. doi: 10.2147/COPD.S445858. eCollection 2024. PubMed 38435125 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Mar 2022, 30 months.

Of 120 industry-sponsored observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's 30 months is above that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2019
First posted
May 24, 2019
StartActual
Aug 21, 2019
Primary completionActual
Mar 4, 2022
CompletionActual
Mar 4, 2022
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03963167
Lead sponsor
Chiesi Italia
Responsible party
Sponsor
First posted
May 24, 2019
Start date
Aug 21, 2019
Primary completion
Mar 4, 2022
Completion
Mar 4, 2022
Last update
Feb 20, 2026

Study contacts

Luca Richeldi, MD
principal investigator · Policlinico Gemelli, Roma (Italy)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion